The Baldwin Insurance Group, Inc. Class A Common Stock
BWIN
$31.87
-0.13%
The Baldwin Insurance Group, Inc. (BWIN) is a U.S.-focused insurance distribution platform operating through three segments: Insurance Advisory Solutions (commercial risk management and employee benefits), Underwriting, Capacity & Technology Solutions (managing general agency operations, reinsurance brokerage, captive management, and technology-enabled products), and Mainstreet Insurance Solutions (personal, commercial, and life & health insurance distributed through community-based channels). The company occupies a distinctive position as an integrated, technology-leveraged insurance distributor rather than a traditional risk-bearing carrier, with roughly 5,020 employees and a market capitalization near $3.1 billion. The current investor narrative centers on BWIN's aggressive acquisition-driven expansion — Q2 2026 revenue grew 31.7% year-over-year to $492.9 million — juxtaposed against persistent GAAP unprofitability (Q2 2026 net loss of $39.0 million) and a heavily leveraged balance sheet with debt-to-equity of 2.95x. Debate among investors hinges on whether the company's organic growth and margin trajectory can eventually translate into sustained GAAP profitability, or whether acquisition-related amortization, interest expense, and integration costs will continue to suppress earnings despite strong top-line momentum.…
BWIN
The Baldwin Insurance Group, Inc. Class A Common Stock
$31.87
Investment Opinion: Should I buy BWIN Today?
Based on the synthesis of data, BWIN warrants a 'Hold' rating. The analyst consensus is 'hold' with an average target price of $32.92, implying just 3.3% upside from the current price of $31.87. The core thesis is that while revenue growth is impressive at 31.7% YoY, the company's persistent GAAP losses, negative gross margin, and high leverage create substantial uncertainty that offsets the growth potential.
Supporting evidence for the Hold includes: 1) Revenue growth of 31.7% YoY in Q2 2026, but this was acquisition-driven and accompanied by a sequential revenue decline from Q1 2026. 2) The forward PE of 12.86x suggests an earnings turnaround, but the wide EPS estimate range ($0.94 to $4.99) highlights low confidence. 3) Operating margin TTM is positive at 7.27%, but net margin is -2.25% due to high interest and amortization expenses. 4) Free cash flow TTM is $43.7 million, which is positive but insufficient to cover $111.0 million in debt repayment in Q2 2026 alone. Compared to industry averages, BWIN's PS ratio of 1.08x is a deep discount, but this is justified by its weak profitability.
The biggest risks that could invalidate the thesis include: 1) A continued decline in gross margin, which turned negative in Q2 2026. 2) Failure to deleverage, with debt-to-equity at 2.95x. 3) Integration challenges from acquisitions that could further pressure earnings. The rating would upgrade to Buy if the company demonstrates sustained positive net income and gross margin recovery above 20%, or if the forward PE compresses below 10x with improving fundamentals. It would downgrade to Sell if revenue growth decelerates below 15% or if gross margin remains negative for multiple quarters. Currently, the stock appears fairly valued relative to its history and peers, with the market pricing in a successful turnaround that has yet to materialize.
Sign up to view all
BWIN 12-Month Price Forecast
BWIN presents a high-risk, high-reward scenario. The company's revenue growth is impressive, but its inability to generate consistent GAAP profits and its heavy debt load are major concerns. The forward PE suggests that the market expects a turnaround, but the wide range of EPS estimates indicates low confidence. The stock's recent rally has been driven by momentum and relative strength, but it is now trading near its 52-week high, leaving little margin for error. I would upgrade to bullish if the company reports positive net income and gross margin recovery in the next two quarters, and downgrade to bearish if revenue growth slows or gross margin remains negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Baldwin Insurance Group, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $32.42 and implied upside of +1.7% versus the current price.
Average Target
$32.42
0 analysts
Implied Upside
+1.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$32 - $33
Analyst target range
BWIN is covered by 6 analysts, with a consensus recommendation of "hold" (recommendation mean of 2.75 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $32.92, which implies approximately +3.3% upside from the current price of $31.87 — a modest potential return that suggests the stock is trading close to fair value according to the analyst community. The consensus leans neutral rather than bullish, with the "hold" rating reflecting analysts' recognition of the company's strong revenue growth but lingering concerns about profitability, leverage, and the sustainability of its acquisition-driven model. The target range spans from a low of $31.00 to a high of $37.00, a spread of $6.00 or approximately 19% of the average target, which signals moderate uncertainty but not extreme divergence in analyst views. The high target of $37.00 implies roughly 16.1% upside and likely assumes successful integration of recent acquisitions, margin expansion toward historical norms, and a clear path to sustained GAAP profitability. The low target of $31.00 implies essentially flat performance and likely prices in continued margin compression, integration challenges, or a more conservative view on the company's ability to deleverage. Recent institutional ratings show a mix of actions: JP Morgan upgraded BWIN from Neutral to Overweight on June 22, 2026, and maintained Overweight on July 13, 2026, while William Blair downgraded from Outperform to Market Perform on September 14, 2026 — a notable negative signal given the timing just before the stock's recent consolidation. UBS has maintained a Buy rating, and Keefe, Bruyette & Woods has maintained Outperform, suggesting that while some analysts see value, others are becoming more cautious. The estimated revenue average of $2.41 billion for the forward period, with a range of $2.26 billion to $2.50 billion, implies continued top-line growth but at a potentially moderating pace relative to the 31.7% YoY growth seen in Q2 2026.
Bulls vs Bears: BWIN Investment Factors
The bull case for BWIN rests on its impressive revenue growth of 31.7% YoY, a forward PE of 12.86x that implies a significant earnings inflection, and strong technical momentum with 48.99% 6-month gains. However, the bear case is equally compelling: negative gross margin in Q2 2026, a 2.95x debt-to-equity ratio, and persistent GAAP losses raise doubts about the sustainability of the business model. Currently, the bear evidence appears stronger due to the gross margin anomaly and high leverage, which pose immediate risks. The most critical tension is whether BWIN can convert its top-line growth into consistent GAAP profitability; if it fails, the stock's recent rally could reverse sharply. Conversely, successful integration of acquisitions and margin recovery could validate the bull thesis and drive the stock toward the high target of $37.
Bullish
- Revenue growth accelerating at 31.7% YoY: Q2 2026 revenue reached $492.9 million, up 31.69% from $374.3 million in Q2 2025, demonstrating robust top-line momentum. This growth significantly outpaces the broader insurance brokerage sector, suggesting market share gains and successful acquisition integration.
- Forward PE of 12.86x implies earnings inflection: Despite a trailing loss, the forward PE of 12.86x based on estimated EPS of $2.94 signals that analysts expect a dramatic swing to profitability. This valuation is attractive for a company growing revenue at over 30%, assuming the earnings turnaround materializes.
- Strong relative strength and momentum: BWIN has outperformed SPY by 34.40% over 6 months and 17.13% over 3 months, with the stock up 48.99% in 6 months. The recent breakout above $32 suggests sustained investor confidence and potential for further gains.
- Analyst high target implies 16.1% upside: The highest analyst target of $37.00 represents a 16.1% upside from the current price of $31.87, reflecting optimism about margin expansion and deleveraging. This target is supported by recent upgrades from JP Morgan and UBS.
Bearish
- Q2 2026 gross margin turned negative: Gross margin plummeted to -1.69% in Q2 2026 from 28.12% in Q2 2025, with gross profit of -$8.3 million. This anomaly, driven by $501.3 million in cost of revenue exceeding revenue, raises serious questions about cost controls and acquisition accounting.
- Heavy debt burden with 2.95x debt-to-equity: Total debt-to-capitalization stands at 75.2%, and interest expense was $45.7 million in Q2 2026 alone. This leverage constrains financial flexibility and amplifies risk, especially with a current ratio of only 1.16.
- Persistent GAAP unprofitability: Q2 2026 net loss was $39.0 million, a deterioration from Q1 2026's $2.3 million profit and Q2 2025's $3.2 million loss. Trailing net margin is -2.25%, and ROE is -5.63%, indicating that the company has not yet proven it can generate consistent GAAP profits.
- Analyst consensus is only 'hold' with minimal upside: The average target price of $32.92 implies just 3.3% upside, and the recommendation mean of 2.75 (hold) reflects analyst caution. Recent downgrade by William Blair to Market Perform on September 14, 2026, adds to the negative sentiment.
BWIN Technical Analysis
BWIN is in a sustained recovery uptrend, with the current price of $31.87 representing a 9.71% gain over the past year and sitting at approximately 94.9% of its 52-week range (52-week low of $15.88, 52-week high of $32.705). This positioning near the upper end of the annual range signals strong momentum but also raises the risk of overextension, particularly given the stock's max drawdown of -49.03% over the observed period, which underscores how sharply this name can reverse. The 6-month gain of 48.99% and YTD advance of 34.02% confirm that the primary trend has been decisively upward since the spring trough. Recent momentum is accelerating: the 1-month change of 12.89% and 3-month change of 20.26% both outpace the 1-year gain of 9.71%, indicating that the stock's advance has gathered pace in the second half of 2026 rather than decelerating. Relative strength versus SPY is strikingly positive across shorter horizons — +10.77% over 1 month, +17.13% over 3 months, and +34.40% over 6 months — though the 1-year relative strength of -6.29% reveals that BWIN lagged the market over the full trailing year, implying the recent surge is a catch-up/re-rating phase rather than persistent long-term outperformance. The stock's beta of 0.999 suggests volatility roughly in line with the broader market, which is notable for a small-cap insurance distributor and implies that position sizing need not be dramatically adjusted for systematic risk, though idiosyncratic event risk (earnings, acquisition announcements) remains elevated given the 5.11 short ratio. Key technical resistance sits at the 52-week high of $32.705, and a decisive breakout above that level — particularly on above-average volume relative to the current 3.39 million share daily average — would confirm the uptrend and potentially open a new leg higher. Support is anchored at the 52-week low of $15.88, with intermediate support likely forming around the $28-$29 zone where the stock consolidated in August and early September 2026; a breakdown below $28 would signal trend deterioration, while a loss of the $15.88 low would represent a catastrophic technical failure.
Beta
1.00
1.00x market volatility
Max Drawdown
-47.6%
Largest decline past year
52-Week Range
$16-$33
Price range past year
Annual Return
+37.8%
Cumulative gain past year
| Period | BWIN Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +0.6% |
| 3m | +21.9% | +2.4% |
| 6m | +24.5% | +7.8% |
| 1y | +37.8% | +15.4% |
| ytd | +34.0% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BWIN Fundamental Analysis
BWIN's revenue trajectory is robustly growing, with Q2 2026 revenue of $492.9 million representing 31.69% year-over-year growth versus Q2 2025's $374.3 million. However, the multi-quarter trend reveals volatility: Q1 2026 revenue of $532.2 million was actually higher than Q2 2026, and Q4 2025 revenue of $347.3 million was the lowest of the trailing four quarters, suggesting seasonality and acquisition timing effects rather than smooth sequential growth. The revenue mix is heavily concentrated in commission revenue at $420.6 million, with consulting and service fees at $43.5 million, profit sharing at $26.1 million, policy/installment fees at $20.7 million, earned premium at $14.2 million, and other insurance revenue at $3.8 million — meaning the company's fortunes are overwhelmingly tied to commission-based distribution economics. The 31.7% growth rate, while impressive, must be scrutinized for whether it is organic or acquisition-driven, and the fact that Q2 2026 revenue declined sequentially from Q1 2026 raises questions about the durability of the growth trajectory. Profitability remains the central concern: Q2 2026 net income was -$39.0 million (net margin of -7.91%), a sharp deterioration from Q1 2026's positive net income of $2.3 million and Q2 2025's modest loss of $3.2 million. Gross margin in Q2 2026 was -1.69%, a dramatic compression from Q2 2025's 28.12% and Q1 2026's 12.74%, driven by a gross profit of -$8.3 million against $501.3 million in cost of revenue — an anomaly that suggests either significant one-time charges, acquisition accounting effects, or a structural cost problem. Operating margin for Q2 2026 was -1.69%, and the trailing twelve-month net margin stands at -2.25%, while the operating margin on a TTM basis is 7.27%, highlighting the enormous gap between operating performance and bottom-line results due to $45.7 million in quarterly interest expense and $58.8 million in depreciation and amortization. The balance sheet is highly leveraged: debt-to-equity of 2.95x, total debt-to-capitalization of 75.2%, and a current ratio of 1.16 indicate limited financial flexibility. Free cash flow on a TTM basis is $43.7 million, but this is dwarfed by the $111.0 million in debt repayment during Q2 2026 alone, and the company's cash flow coverage ratio of just 0.017 underscores how thin cash generation is relative to obligations. ROE is -5.63% and ROA is -0.91%, confirming that the company is not generating adequate returns on its capital base, and the negative PCF ratio of -55.50 reflects the mismatch between cash flow and valuation. The company's reliance on external financing is evident from Q1 2026's $606.5 million in net cash from financing activities, which funded $491.2 million in investing outflows (largely acquisitions), indicating that growth is being financed through debt and equity issuance rather than internal cash generation.
Quarterly Revenue
$492939000.0B
2026-06
Revenue YoY Growth
+31.7%
YoY Comparison
Gross Margin
-1.7%
Latest Quarter
Free Cash Flow
$43707000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BWIN Overvalued?
Because BWIN's trailing net income is negative (EPS of -$0.02, trailing PE of -48.06), the PE ratio is not meaningful as a primary valuation metric; instead, the PS ratio of 1.08x is the appropriate lead metric, supplemented by the EV/Sales of 3.45x and EV/EBITDA of 16.66x. The forward PE of 12.86x is particularly instructive: it implies that analysts expect the company to swing to meaningful profitability, with estimated EPS averaging $2.94 for the forward period — a dramatic reversal from the current trailing loss. The gap between the negative trailing PE and the positive forward PE of 12.86x signals that the market is pricing in a substantial earnings inflection, likely driven by the absence of one-time charges, acquisition integration synergies, and operating leverage on a growing revenue base. On a PS basis, BWIN trades at 1.08x trailing sales, which is low in absolute terms but must be contextualized against the company's negative net margin of -2.25% and gross margin of 12.76%. Compared to the broader insurance brokerage sector, where established players like Marsh McLennan and Aon typically trade at 3-5x sales with net margins in the mid-teens, BWIN's 1.08x PS represents a significant discount — roughly a 60-75% discount to sector leaders — but this discount is justified by BWIN's negative earnings, 2.95x debt-to-equity leverage, and unproven ability to convert revenue growth into GAAP profits. The EV/EBITDA of 16.66x is more moderate and suggests that on an operating basis, the company is not egregiously expensive, though the EV/Sales of 3.45x is elevated relative to the PS ratio due to the company's substantial debt load. Historically, BWIN's PS ratio has ranged from a high of 10.19x in Q4 2021 to a low of 2.85x in Q1 2026, with the current 1.08x sitting well below even the lowest recent historical level — a stark compression that reflects either a significant value opportunity or a fundamental deterioration in the market's growth and profitability expectations. The PB ratio of 2.72x is near the middle of its historical range (2.08x to 5.35x), suggesting that on a book value basis, the stock is not at an extreme. The forward PE of 12.86x, if achieved, would represent a reasonable valuation for a company growing revenue at 31.7%, but the wide dispersion in estimated EPS ($0.94 to $4.99) highlights the enormous uncertainty surrounding the company's earnings trajectory.
PE
-48.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for BWIN. The company's debt-to-equity ratio of 2.95x and total debt-to-capitalization of 75.2% indicate a heavily leveraged balance sheet, with interest expense of $45.7 million in Q2 2026 consuming a large portion of operating income. The negative gross margin of -1.69% in Q2 2026, a stark reversal from 28.12% in Q2 2025, suggests either severe cost overruns or acquisition-related charges that could persist. Additionally, the current ratio of 1.16 leaves little room for liquidity shocks, and free cash flow of $43.7 million TTM is insufficient to cover debt obligations, as evidenced by the cash flow coverage ratio of 0.017.
Market and competitive risks are also pronounced. BWIN trades at a PS ratio of 1.08x, which is a steep discount to peers like Marsh McLennan and Aon (3-5x sales), but this discount is warranted by its negative net margin and high leverage. If the company fails to improve profitability, the stock could face further multiple compression. The beta of 0.999 suggests market-level volatility, but idiosyncratic risks such as integration challenges or regulatory changes in insurance distribution could amplify losses. The recent downgrade by William Blair on September 14, 2026, highlights growing analyst skepticism, and the short ratio of 5.11 indicates that short sellers are betting against a near-term turnaround.
In a worst-case scenario, a continued deterioration in gross margins, coupled with rising interest rates or a recession, could lead to a liquidity crisis. The 52-week low of $15.88 represents a potential downside of approximately 50% from the current price of $31.87. If the company misses earnings expectations or announces further acquisition-related charges, the stock could retest that low, especially given the max drawdown of -49.03% over the observed period. Investors could lose nearly half their capital in such an adverse scenario, underscoring the high-risk nature of this investment.
FAQ
The key risks include: 1) Financial risk: high debt-to-equity of 2.95x and interest expense of $45.7 million per quarter, with a current ratio of only 1.16. 2) Operational risk: gross margin turned negative in Q2 2026 at -1.69%, indicating potential cost control issues. 3) Market risk: the stock is trading near its 52-week high, and a failure to meet earnings expectations could trigger a sharp sell-off. 4) Competitive risk: as a smaller player, BWIN faces competition from larger, more established brokers. These risks are ranked from highest to lowest severity, with financial and operational risks being the most immediate.
Our 12-month forecast for BWIN includes three scenarios: Bull case (25% probability) with a target range of $37-$40, assuming successful integration and profitability; Base case (55% probability) with a target range of $31-$34, assuming moderate growth but continued profitability challenges; and Bear case (20% probability) with a target range of $15.88-$25, assuming a recession or integration failures. The base case is most likely, with the key assumption that revenue growth moderates to 15-20% and gross margin stabilizes around 10-15%. The stock is currently trading near the middle of the base case range.
BWIN appears fairly valued to slightly undervalued on a forward basis. The forward PE of 12.86x is attractive for a company growing revenue at over 30%, but this assumes an earnings turnaround that has not yet occurred. The PS ratio of 1.08x is a deep discount to peers like Marsh McLennan (3-5x sales), but this discount is justified by BWIN's negative net margin and high leverage. The EV/EBITDA of 16.66x is moderate. Overall, the market is pricing in a successful turnaround, and if that fails, the stock could be overvalued.
BWIN is not a straightforward buy at current levels. While the company shows strong revenue growth of 31.7% YoY, it remains unprofitable with a net margin of -2.25% and carries a high debt load (debt-to-equity of 2.95x). The analyst consensus is 'hold' with an average target of $32.92, implying only 3.3% upside. The biggest downside risk is a retest of the 52-week low of $15.88, which would represent a 50% loss. Therefore, it may only be suitable for aggressive investors who believe in the long-term turnaround story and can tolerate significant volatility.
BWIN is more suitable for long-term investment (at least 2-3 years) for investors who believe in the company's acquisition-driven growth strategy and its potential to achieve sustainable profitability. The stock is not ideal for short-term trading due to its high volatility (beta of 0.999, max drawdown of -49.03%) and lack of dividend income. The company's earnings visibility is low, with a wide range of EPS estimates, making it risky for short-term positions. A minimum holding period of 2-3 years would allow time for integration synergies to materialize and for the balance sheet to deleverage.